Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTRAIN-SUI study of orforglipron in women with stress urinary incontinence and obesity or overweight
2025-522514-23-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in stress urinary incontinence (SUI) comparing Orforglipron once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline in incontinence episode frequency. Planned start Feb 2026; status: authorised.
02
Drugs
orforglipron
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on 2025-522514-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522514-23-00.